Binding of antipsychotic drugs to cortical 5-HT(2A) receptors: A PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients

American Journal of Psychiatry

Volumn 155, Issue 4, 1998, Pages 505-508

  Trichard, Christian ^a   Paillère Martinot, Marie Laure ^b   Attar Levy, Dominique ^b   Recassens, Christophe ^b   Monnet, François ^b   Martinot, Jean Luc ^b  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; FLUORINE 18; NEUROLEPTIC AGENT; SEROTONIN 2A RECEPTOR; SETOPERONE;

ADULT; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BINDING SITE; DRUG RECEPTOR BINDING; FEMALE; HUMAN; MALE; MENTAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RADIOACTIVITY; RECEPTOR BLOCKING; SCHIZOPHRENIA;

EID: 2642638739     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.4.505     Document Type: Article

References (20)

1. 2 pKi values.] Pharmacol Exp Ther 1989; 251:238-251
2. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995; 152:1444-1449
3. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
4. 18F-labeled setoperone. J Neurochem 1990; 54:1744-1754
5. 1 antagonists, and opiates. Drug Dev Res 1986; 8:119-131
6. Chivers JK, Gommeren W, Eeysen JE, Jenner P, Marsden D: Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors. J Pharm Pharmacol 1988; 40:415-421
7. 3) as a target for neuroleptics. Nature 1991; 347:146-151
8. 18F-setoperone studied in humans using positron emission tomography. J Neurochem 1992; 58:2303-2310
9. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ: A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984; 15:217-227
10. 2 receptors in Alzheimer's disease. Brain 1993; 116:497-510
11. Marcusson JO, Morgan DG, Winblad B, Finch CE: Serotonin-2 binding sites in human frontal cortex and hippocampus: selective loss of S-2A sites with age. Brain Res 1984; 311:51-56
12. 2 receptors of the human brain postmortem. Brain Res 1990; 519:223-227
13. Andree TH, Mikuni M, Tong CY, Koenig JI, Meltzer HY: Differential effect of subchronic treatment with various neuroleptic agents on serotonin2 receptors in rat cerebral cortex. J Neurochem 1986; 46:191-197
14. 2 receptor density in rat cerebral cortex. Life Sci 1989; 45:1397-1406
15. Kane J, Honigfeld G, Singer J, Meltzer HY: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
16. Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V, Klerman G: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7:377-384
17. Meltzer HY: The effect of clozapine and other atypical antipsychotic drugs on negative symptoms, in Negative Versus Positive Schizophrenia. Edited by Marneros A, Andreasen NC, Tsuang MT. New York, Springler-Verlag, 1991, pp 365-376
18. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F: Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995; 166:68-72
19. Paillère-Martinot M-L, Lecrubier Y, Martinot J-L, Aubin F: Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 1995; 152:130-133
20. 2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berl) 1996; 124:154-158